The effect of specialized cancer treatment centers on treatment efficacy in hodgkin's lymphoma;Einfluss von onkologischen Behandlungszentren auf den Therapieerfolg beim Hodgkin-Lymphom

Deutsches Arzteblatt International

Volumn 109, Issue 51-52, 2012, Pages 893-899

  Klimm, Beate ^a   Brillant, Corinne ^a   Skoetz, Nicole ^a   Müller, Horst ^a   Engert, Andreas ^a   Borchmann, Peter ^a  

^a Department i Haematology Immunology Infectiology Intensive Care and Oncology   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CENTER; CANCER PROGNOSIS; CANCER THERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; GERMANY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MULTICENTER STUDY; PATIENT CARE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; ADULT; CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; MALE; MORTALITY; PREVALENCE; RISK FACTOR; SURVIVAL; SURVIVAL RATE; UTILIZATION;

ADULT; CANCER CARE FACILITIES; FEMALE; GERMANY; HODGKIN DISEASE; HUMANS; MALE; ONCOLOGY SERVICE, HOSPITAL; PREVALENCE; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84873946879     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0893     Document Type: Article

References (28)

1. Diehl V: Therapie des Morbus Hodgkin: Erfahrungen der Deutschen Hodgkin-Studiengruppe über vier Studiengenerationen. Dtsch Arztebl 2002; 99(25): A 1760.
2. Klimm B, Diehl V, Pfistner B, Engert A: Current treatment strategies of the German Hodgkin Study Group (GHSG). Eur J Haematol Suppl 2005; 66: 125-34.
3. Dühmke E, Franklin J, Pfreundschuh M, et al.: Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001; 19: 2905-14.
4. Sieber M, Tesch H, Pfistner B, et al.: Rapidly alternating COPP/ ABV/IMEP is not superior to conventional alternating COPP/ ABVD in combination with extended-field radiotherapy in intermediate- stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 2002; 20: 476-84.
5. Sieber M, Tesch H, Pfistner B, et al.: Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol 2004; 15: 276-82.
6. Engert A, Franklin J, Eich HT, et al.: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495-502.
7. Engert A, Schiller P, Josting A, et al.: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early- stage unfavorable Hodgkin's Lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3601-8.
8. Diehl V, Franklin J, Pfreundschuh M, et al.: Standard and increased- dose BEACOPP chemotherapy compared with COPPABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-95.
9. Engert A, Pluetschow A, Eich HT, et al.: Reduced treatment intensity in patients with early-stage Hodgkin's Lymphoma. N Engl J Med 2010; 363: 640-52.
10. Eich HT, Diehl V, Görgen H, et al.: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199-206.
11. Borchmann P, Haverkamp H, Diehl V, et al.: Eight cycles of esca - lated-dose BEACOPP compared with four cycles of escalateddose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advancedstage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29: 4234-42.
12. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K: The financing of drug trials by pharmaceutical companies and its consequences: Part 1. A Qualitative, systematic review of the literature on possible influences on the findings, Protocols, and quality of drug trials. Dtsch Arztebl Int 2010; 107(16): 279-85.
13. Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, Ludwig WD: The Financing of Drug Trials by Pharmaceutical Companies and Its Consequences: Part 2. A Qualitative, Systematic Review of the Literature on Possible Influences on Authorship, Access to Trial Data, and Trial Registration and Publication. Dtsch Arztebl Int 2010; 107(17): 295-301.
14. Terschüren C, Gierer S, Brillant C, Paulus U, Löffler M, Hoffmann W: Are patients with Hodgkin lymphoma and high-grade non- Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany? Ann Oncol 2010; 21: 2045-51.
15. Brillant C, Terschueren C, Gierer S, et al.: Differences in survival rates for patients with Hodgkin Lymphoma, who were treated inside vs. outside therapy optimisation protocols in Germany. ASH Annual Meeting Abstracts. Blood 2007; 110: 2321a.
16. Baumann W, Nonnenmacher A, Weiß B, Schmitz S: Patient satisfaction with care in office-based oncology practices. Dtsch Arztebl Int 2008; 105(50): 871-7.
17. Hillner BE, Smith TJ, Desch CE: Hospital and physician volume or specialization and outcomes in cancer treatment: Importance in quality of cancer care. J Clin Oncol 2000; 18: 2327-40.
18. Hollenbeck BK, Dunn RL, Miller DC, Daignault S, Taub DA, Wei JT: Volume-based referral for cancer surgery: informing the debate. J Clin Oncol 2007; 25: 91-6.
19. Loberiza FR Jr, Zhang MJ, Lee SJ, et al.: Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005; 105: 2979-87.
20. Frassoni F, Labopin M, Powles R, et al.: Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 2000; 355: 1393-8.
21. Davis S, Dahlberg S, Myers MH, Chen A, Steinhorn SC: Hodgkin's disease in the United States: a comparison of patient characteristics and survival in the Centralized Cancer Patient Data System and the Surveillance, Epidemiology, and End Results Program. J Natl Cancer Inst 1987; 78: 471-8.
22. Schrag D, Earle C, Xu F, et al.: Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst 2006; 98: 163-71.
23. Earle CC, Schrag D, Neville BA, et al.: Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006; 98: 172-80.
24. Peterson ED, Coombs LP, DeLong ER, Haan CK, Ferguson TB: Procedural volume as a marker of quality for CABG surgery. JAMA 2004; 291: 195-201.
25. Lipscomb J: Transcending the volume-outcome relationship in cancer care. J Natl Cancer Inst 2006; 98: 151-4.
26. Geraedts M, de Cruppe W: Controversial study results in relation to minimum volume standards. Z Arztl Fortbild Qualitatssich 2006; 100: 87-91.
27. Bender R, Grouven U: Possibilities and limitations of statistical regression models for the calculation of threshold values for minimum provider volumes. Z Arztl Fortbild Qualitatssich 2006; 100: 93-98.
28. Grouven U, Kuchenhoff H, Schrader P, Bender R: Flexible regression models are useful tools. Epidemiol 2008; 61: 1125-31.